TY  - GEN
AU  - Jamieson,David
AU  - Griffin,Melanie J
AU  - Sludden,Julieann
AU  - Drew,Yvette
AU  - Cresti,Nicola
AU  - Swales,Karen
AU  - Merriman,Mark
AU  - Allen,Rodger
AU  - Bevan,Paul
AU  - Buerkle,Markus
AU  - Mala,Carola
AU  - Coyle,Vicky
AU  - Rodgers,Lisa
AU  - Dean,Emma
AU  - Greystoke,Alastair
AU  - Banerji,Udai
AU  - Wilson,Richard H
AU  - Evans,T R Jeffery
AU  - Anthoney,Alan
AU  - Ranson,Malcolm
AU  - Boddy,Alan V
AU  - Plummer,Ruth
TI  - A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
SN  - 1879-0852
PY  - 2017///0808
KW  - Abdominal Pain
KW  - chemically induced
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Allosteric Regulation
KW  - Anorexia
KW  - Bile Duct Neoplasms
KW  - drug therapy
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cholangiocarcinoma
KW  - Chromatography, High Pressure Liquid
KW  - Chromatography, Liquid
KW  - Colorectal Neoplasms
KW  - Diarrhea
KW  - Drug Eruptions
KW  - etiology
KW  - Esophageal Neoplasms
KW  - Fatigue
KW  - Female
KW  - Glycogen Synthase Kinase 3 beta
KW  - drug effects
KW  - Humans
KW  - Lung Neoplasms
KW  - MAP Kinase Kinase 1
KW  - antagonists & inhibitors
KW  - MAP Kinase Kinase 2
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Mesothelioma
KW  - Middle Aged
KW  - Mitogen-Activated Protein Kinase 1
KW  - Mitogen-Activated Protein Kinase 3
KW  - Nausea
KW  - Neoplasms
KW  - Pancreatic Neoplasms
KW  - Phosphoproteins
KW  - Protein Kinase Inhibitors
KW  - adverse effects
KW  - Proto-Oncogene Proteins c-akt
KW  - Ribosomal Protein S6 Kinases, 70-kDa
KW  - Tandem Mass Spectrometry
KW  - Uterine Cervical Neoplasms
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ejca.2016.08.026
ER  -